Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Sponsor
Czech Lymphoma Study Group
Study ID
NCT04913103
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Lymphoma, Mantle-Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Polatuzumab vedotin — DRUG
    treatment by a study drug polatuzumab-vedotin, i.v.
  • Bendamustine Hydrochloride — DRUG
    treatment by a study drug bendamustin i.v.
  • Rituximab — DRUG
    treatment by a study drug rituximab, i.v.

Study Details

A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine kinase inhibitor

Key Dates

Start date
Sep 1, 2021
Status verified
May 2021
Primary completion
Aug 31, 2026
Completion
Aug 31, 2027

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: single arm, open-label
    combination of polatuzumab-vedotin, bendamustine and rituximab

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: 4 years ]

Central Contacts